Pharma doubles down on AI to win trust—and market share

The gist
Pharma giants like Pfizer and Novartis are betting big on AI to rebuild trust and drive market share, using data-driven strategies to personalize engagement and supercharge patient outcomes.
What to know
- 81% of U.S. physicians now use AI tools, with 65% adopting OpenEvidence in April 2026, pushing pharma marketers to optimize content for AI-powered clinical queries.
- GoodRx's AI-driven platform boosted its Google AI Overview visibility by 37% thanks to a potent mix of trusted health info, transparent pricing, and pharmacy access.
- Real-time audience insights and authoritative AI plug-ins are key to pharma's ROI, revealing exactly what clinical questions healthcare providers are asking.
AI Bridges Trust Gap
Pharma giants are using advanced AI analytics to deliver personalized, evidence-backed insights, strengthening provider relationships and improving patient care.
Pharma leaders are increasingly turning to AI-driven data analysis as a strategic tool to bridge longstanding gaps in trust and access within healthcare. By harnessing sophisticated algorithms to analyze vast datasets, companies like Pfizer and Novartis aim to enhance healthcare provider engagement through more personalized, evidence-based insights that support clinical decision-making. This shift not only fosters greater transparency and confidence among providers but also translates into improved patient outcomes by ensuring treatments are better tailored and more accessible.
Share-of-Answer Takes Lead
Pharma marketers are shifting from broad reach to precision targeting, using real-time AI data to ensure their brands are cited in critical clinical queries.
As 81% of U.S. physicians incorporate AI tools into clinical practice and 65% used OpenEvidence in April 2026 alone, pharma marketers are compelled to evolve beyond traditional share-of-voice metrics toward data-driven share-of-answer strategies that prioritize being cited in AI-powered clinical queries. This shift demands optimizing content specifically for AI answer engines and integrating dynamic affinity data, such as PharmaForceIQ’s platform which maps healthcare provider behavior across consumer large language models and clinical AI platforms using national provider identifiers, to ensure relevance and visibility where clinical decisions are increasingly influenced.
Effective AI marketing spend hinges on granular, continuously updated audience insights that reveal where healthcare providers engage and what drives their interactions on AI platforms. Stephen Onikoro underscores this by noting, "while every platform can likely pitch impressive reach, that reach only matters if your customers are there," highlighting the critical risk of poor ROI without precise audience targeting. By leveraging agent plug-ins that supply authoritative information to AI models and feed marketers real-time signals about the clinical questions and keywords HCPs engage with, pharma can tailor messaging to the exact needs of clinicians, thereby enhancing the impact of share-of-answer marketing.
Utility Drives Patient Action
AI-powered platforms like GoodRx are uniting trusted content with actionable savings and access tools, turning awareness into real treatment starts.
Pharma companies are increasingly leveraging AI-driven engagement platforms like GoodRx to bridge the critical gap between raising awareness and enabling actionable treatment decisions. By integrating trusted health information with transparent pricing and pharmacy access, GoodRx exemplifies how combining content with practical savings and access tools enhances discoverability and supports patients in initiating therapy. This approach is reflected in GoodRx’s 37% increase in visibility within Google AI Overviews by early 2026, underscoring the value of utility-driven engagement that meets consumers at pivotal healthcare decision moments.
While AI accelerates access to health information, it does not simplify the inherent complexity of treatment decisions, prompting a new mandate for pharma brands to facilitate seamless transitions from inquiry to action. Coordinated AI-driven engagement strategies tailored to both consumers and healthcare providers address this challenge by simultaneously tackling clinical decision-making, affordability, and access. This synchronized approach creates a clearer, audience-appropriate path from demand generation to therapy initiation, ensuring that both patients and providers receive the support needed to move confidently toward treatment.